Pulmonary Hypertension Management.
Personalized, physician-led pulmonary hypertension management with direct access to your cardiology team. Proactive monitoring. Faster interventions. Better outcomes.
Understanding pulmonary hypertension management.
Pulmonary hypertension (PH) is defined as a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest, a threshold updated by the 6th World Symposium on Pulmonary Hypertension in 2018 (lowered from 25 mmHg). The condition encompasses five WHO groups with distinct etiologies: pulmonary arterial hypertension (PAH, Group 1), PH due to left heart disease (Group 2), PH due to lung disease (Group 3), chronic thromboembolic PH (CTEPH, Group 4), and PH with unclear or multifactorial mechanisms (Group 5). Accurate classification is critical because targeted vasodilator therapies that are life-saving in Group 1 PAH can be harmful in Group 2 or 3 PH. PAH, though relatively rare (affecting 15-50 per million adults), is a progressive and ultimately fatal disease without treatment. Even with modern combination therapy — including prostacyclin pathway agents, endothelin receptor antagonists (ERAs), and phosphodiesterase-5 inhibitors (PDE5i) or soluble guanylate cyclase stimulators — 5-year survival remains approximately 60-70%. The AMBITION trial demonstrated that upfront combination therapy with ambrisentan and tadalafil reduced clinical failure by 50% compared to monotherapy. Our concierge pulmonary hypertension program provides expert WHO group classification, right heart catheterization coordination, guideline-directed targeted therapy initiation and optimization, and ongoing hemodynamic and functional monitoring — all managed by cardiologists with advanced training in pulmonary vascular disease.
Why concierge cardiology for this condition.
Pulmonary hypertension is one of the most complex conditions in cardiovascular medicine. Misclassification of WHO group leads to inappropriate therapy. Under-treatment of Group 1 PAH — using monotherapy when combination therapy is indicated — shortens survival. Patients on parenteral prostacyclin therapy require meticulous line care, dose titration, and emergency planning. And the clinical trajectory of PH demands frequent reassessment: a patient who was stable at the last visit may be progressing toward right heart failure. Concierge care provides quarterly comprehensive PH assessments including 6-minute walk test, NT-proBNP, and functional class evaluation; right heart catheterization coordination at diagnosis and with clinical deterioration; medication management for complex regimens including prostacyclin analogs, ERAs, and PDE5i; same-day access for worsening dyspnea, syncope, or signs of right heart failure; and coordination with pulmonary hypertension centers of excellence for transplant evaluation when needed. For a disease where timely therapy escalation can mean the difference between years of functional life and rapid decline, this level of access and monitoring is not a luxury — it is a medical necessity.
What we monitor.
Our management approach.
Expected outcomes.
Related concierge services.
Access expert pulmonary hypertension management with specialized hemodynamic monitoring and targeted therapy.
Direct physician access, proactive monitoring, and personalized care plans. Concierge cardiology starting at $295/month.